Showing 1991-2000 of 5316 results for "".
How to Evaluate EHRs in a Switcher's Market
https://practicaldermatology.com/topics/practice-management/how-to-evaluate-ehrs-in-a-switchers-market/21031/Six questions that can help potential users evaluate a product's value.Fat Chance
https://practicaldermatology.com/topics/general-topics/fat-chance/21037/Experts weigh in on today's non-invasive fat reduction techniques.Reach Your Customers
https://practicaldermatology.com/topics/practice-management/reach-your-customers/21079/Strategic messaging and marketing opportunities for your practice.Win Recognition for Your Practice with Strong Online Content
https://practicaldermatology.com/topics/practice-management/win-recognition-for-your-practice-with-strong-online-content/21095/In a crowded online space, you need an effective content strategy to earn attention and recognition from your target audience on a consistent basis.New Products / Therapeutics Focus: Skin Cancer
https://practicaldermatology.com/topics/practice-management/new-products-therapeutics-focus-skin-cancergy/21120/Currents
https://practicaldermatology.com/topics/practice-management/currents/21127/Consolidating Regulatory Penalties: Introducing MIPS
https://practicaldermatology.com/topics/practice-management/consolidating-regulatory-penalties-introducing-mips/21140/A new system will consolidate Meaningful Use, Value-Based Modifier, and PQRS into one program. Here's what you need to know.Top 10 Ways to Improve Acne Treatment
https://practicaldermatology.com/topics/practice-management/top-10-ways-to-improve-acne-treatment/21151/Tips for enhancing treatment regimens for better results.Pruritus: A Marker For Cancer?
https://practicaldermatology.com/topics/practice-management/pruritus-a-marker-for-cancer/21181/Though the relationship is well known, new studies validate concerns regarding the link between pruritus and malignancy.Biologics and Pediatric Psoriasis
https://practicaldermatology.com/topics/practice-management/biologics-and-pediatric-psoriasis/21196/Though data has been lacking in recent years, the use of biologics in pediatric and adolescent patients deserves more consideration.